Pharma Influence & Why Patient Voices Matter
Lobbying Power: Eli Lilly, Novo Nordisk, and Government Access
Why GLP-1 Medication Access Is at Risk
Introducing Sabina Hemi & the Mission of GLP Winner
Why Compounded GLP-1s Matter for Real Patients
The Federal “Safe Drugs” Bill: What It Claims vs What It Does
Why This Bill Raises Red Flags for Patients
What Real Compounding Safety Reform Would Look Like
How Compounding Pharmacies Are Actually Regulated Today
Prescription Reporting vs Patient Safety
Is This Bill About Safety or Litigation Data?
Dose Flexibility, Personalized Medicine, and Compounding
Florida SB 860: A Direct Threat to Compounded GLP-1s
Why Florida Compounding Impacts the Entire Country
Why Obesity Medications Are Being Singled Out
Active Pharmaceutical Ingredients (API): What Patients Should Know
FDA Oversight, the “Green List,” and State Overreach
Why Florida’s API & COA Requirements Don’t Add Up
FDA Inspection Backlogs & Impossible Compliance Standards
Branded Drug Safety Issues vs Compounding Scrutiny
Catalent, Novo Nordisk, and Manufacturing Concerns
Counterfeit Ozempic: The Overlooked Safety Crisis
Why Supply Chain Integrity Should Be the Priority
What Patients Can Do Right Now
Petitions, Advocacy, and Making Your Voice Heard
Florida Residents: Why Local Action Matters
Final Thoughts on Access, Power, and Patient Advocacy

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.